JW Shinyak, 3Q Operating Profit 2.6 Billion KRW... Up 15.7% YoY

JW Shinyak announced on the 9th that its Q3 operating profit on a separate basis was tentatively estimated at 2.602 billion KRW, a 15.7% increase compared to the same period last year.

JW Shinyak CI. [Image provided by JW Shinyak]

During the same period, sales grew by 4.3% to 26.237 billion KRW. Net profit increased by 42% to 1.91 billion KRW.

JW Shinyak explained that the Q3 performance was driven by continued growth in the internal medicine market and steady sales of clinic pharmaceuticals targeting specialized hospitals and clinics in dermatology, pediatrics, otolaryngology, and urology.

Additionally, the company added that new products such as the peptic ulcer and gastroesophageal reflux disease treatment 'Bestidin 40mg', the hair loss treatment 'L-Kranel Alpha Solution', and the launch of the influenza vaccine 'Skycellflu Quadrivalent' contributed to the growth trend in performance.

A JW Shinyak official stated, "Various specialty pharmaceuticals leading the clinic market continue to record steady growth," and added, "We will further strive to expand our business areas to secure future growth potential."